Prevention of acute venous stent-induced thrombosis using inhibition of fxii

Khanh P. Nguyen, Michael Wallisch, Jennifer Johnson, Andras Gruber, Monica Hinds

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Acute proximal lower extremity deep vein thrombosis (DVT) affects 1-2 per 1000 patients annually and confers significant acute and chronic morbidity and mortality. Pulmonary embolism (PE) and post-thrombotic syndrome (PTS) remain prevalent and hard-to-manage complications after DVT despite medical therapy. Treatment and recanalization of symptomatic, iliofemoral venous stenosis or obstruction, the long-term sequelae of DVT and DVT-associated PTS, by angioplasty and stenting is indicated in select ambulatory patients. While venous stenting can improve and restore blood flow in some cases, patency rates are poor with 1-year patency rates of 70% and significantly lower 5-year patency rates. After stenting, medical management of DVT requires either anti-platelet therapy and/or anticoagulation, which improves primary patency rates but carries a significant, 2-4% annual risk of major bleeding. Modern anticoagulation therapy including vitamin K antagonists, direct thrombin inhibitors and Factor X inhibitors have significant bleeding risks due to the impairment of hemostasis. As many patients require long-term medical therapy, development of a novel anticoagulant with a lower risk profile is critical. Since coagulation factor XII (FXII) supports contact activation of blood but has no known contribution to hemostasis, we sought to determine the thrombogenic role of FXII in an acute ex vivo venous stent model utilizing a FXII-neutralizing monoclonal antibody, 5C12.

Original languageEnglish (US)
Title of host publicationSociety for Biomaterials Annual Meeting and Exposition 2019
Subtitle of host publicationThe Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting
PublisherSociety for Biomaterials
Number of pages1
ISBN (Electronic)9781510883901
StatePublished - Jan 1 2019
Event42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Seattle, United States
Duration: Apr 3 2019Apr 6 2019

Publication series

NameTransactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium
Volume40
ISSN (Print)1526-7547

Conference

Conference42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence
CountryUnited States
CitySeattle
Period4/3/194/6/19

Fingerprint

Factor XII
Stents
Venous Thrombosis
Thrombosis
Blood
Factor X
Hemostasis
Monoclonal antibodies
Antithrombins
Vitamin K
Vitamins
Platelets
Coagulation
Anticoagulants
Hemorrhage
Therapeutics
Chemical activation
Monoclonal Antibodies
Neutralizing Antibodies
Pulmonary Embolism

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Biotechnology
  • Biomaterials
  • Materials Chemistry

Cite this

Nguyen, K. P., Wallisch, M., Johnson, J., Gruber, A., & Hinds, M. (2019). Prevention of acute venous stent-induced thrombosis using inhibition of fxii. In Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium; Vol. 40). Society for Biomaterials.

Prevention of acute venous stent-induced thrombosis using inhibition of fxii. / Nguyen, Khanh P.; Wallisch, Michael; Johnson, Jennifer; Gruber, Andras; Hinds, Monica.

Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials, 2019. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium; Vol. 40).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Nguyen, KP, Wallisch, M, Johnson, J, Gruber, A & Hinds, M 2019, Prevention of acute venous stent-induced thrombosis using inhibition of fxii. in Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium, vol. 40, Society for Biomaterials, 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence, Seattle, United States, 4/3/19.
Nguyen KP, Wallisch M, Johnson J, Gruber A, Hinds M. Prevention of acute venous stent-induced thrombosis using inhibition of fxii. In Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials. 2019. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium).
Nguyen, Khanh P. ; Wallisch, Michael ; Johnson, Jennifer ; Gruber, Andras ; Hinds, Monica. / Prevention of acute venous stent-induced thrombosis using inhibition of fxii. Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials, 2019. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium).
@inproceedings{f1f6ca11ba6046849202504b1991b3ba,
title = "Prevention of acute venous stent-induced thrombosis using inhibition of fxii",
abstract = "Acute proximal lower extremity deep vein thrombosis (DVT) affects 1-2 per 1000 patients annually and confers significant acute and chronic morbidity and mortality. Pulmonary embolism (PE) and post-thrombotic syndrome (PTS) remain prevalent and hard-to-manage complications after DVT despite medical therapy. Treatment and recanalization of symptomatic, iliofemoral venous stenosis or obstruction, the long-term sequelae of DVT and DVT-associated PTS, by angioplasty and stenting is indicated in select ambulatory patients. While venous stenting can improve and restore blood flow in some cases, patency rates are poor with 1-year patency rates of 70{\%} and significantly lower 5-year patency rates. After stenting, medical management of DVT requires either anti-platelet therapy and/or anticoagulation, which improves primary patency rates but carries a significant, 2-4{\%} annual risk of major bleeding. Modern anticoagulation therapy including vitamin K antagonists, direct thrombin inhibitors and Factor X inhibitors have significant bleeding risks due to the impairment of hemostasis. As many patients require long-term medical therapy, development of a novel anticoagulant with a lower risk profile is critical. Since coagulation factor XII (FXII) supports contact activation of blood but has no known contribution to hemostasis, we sought to determine the thrombogenic role of FXII in an acute ex vivo venous stent model utilizing a FXII-neutralizing monoclonal antibody, 5C12.",
author = "Nguyen, {Khanh P.} and Michael Wallisch and Jennifer Johnson and Andras Gruber and Monica Hinds",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
series = "Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium",
publisher = "Society for Biomaterials",
booktitle = "Society for Biomaterials Annual Meeting and Exposition 2019",

}

TY - GEN

T1 - Prevention of acute venous stent-induced thrombosis using inhibition of fxii

AU - Nguyen, Khanh P.

AU - Wallisch, Michael

AU - Johnson, Jennifer

AU - Gruber, Andras

AU - Hinds, Monica

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Acute proximal lower extremity deep vein thrombosis (DVT) affects 1-2 per 1000 patients annually and confers significant acute and chronic morbidity and mortality. Pulmonary embolism (PE) and post-thrombotic syndrome (PTS) remain prevalent and hard-to-manage complications after DVT despite medical therapy. Treatment and recanalization of symptomatic, iliofemoral venous stenosis or obstruction, the long-term sequelae of DVT and DVT-associated PTS, by angioplasty and stenting is indicated in select ambulatory patients. While venous stenting can improve and restore blood flow in some cases, patency rates are poor with 1-year patency rates of 70% and significantly lower 5-year patency rates. After stenting, medical management of DVT requires either anti-platelet therapy and/or anticoagulation, which improves primary patency rates but carries a significant, 2-4% annual risk of major bleeding. Modern anticoagulation therapy including vitamin K antagonists, direct thrombin inhibitors and Factor X inhibitors have significant bleeding risks due to the impairment of hemostasis. As many patients require long-term medical therapy, development of a novel anticoagulant with a lower risk profile is critical. Since coagulation factor XII (FXII) supports contact activation of blood but has no known contribution to hemostasis, we sought to determine the thrombogenic role of FXII in an acute ex vivo venous stent model utilizing a FXII-neutralizing monoclonal antibody, 5C12.

AB - Acute proximal lower extremity deep vein thrombosis (DVT) affects 1-2 per 1000 patients annually and confers significant acute and chronic morbidity and mortality. Pulmonary embolism (PE) and post-thrombotic syndrome (PTS) remain prevalent and hard-to-manage complications after DVT despite medical therapy. Treatment and recanalization of symptomatic, iliofemoral venous stenosis or obstruction, the long-term sequelae of DVT and DVT-associated PTS, by angioplasty and stenting is indicated in select ambulatory patients. While venous stenting can improve and restore blood flow in some cases, patency rates are poor with 1-year patency rates of 70% and significantly lower 5-year patency rates. After stenting, medical management of DVT requires either anti-platelet therapy and/or anticoagulation, which improves primary patency rates but carries a significant, 2-4% annual risk of major bleeding. Modern anticoagulation therapy including vitamin K antagonists, direct thrombin inhibitors and Factor X inhibitors have significant bleeding risks due to the impairment of hemostasis. As many patients require long-term medical therapy, development of a novel anticoagulant with a lower risk profile is critical. Since coagulation factor XII (FXII) supports contact activation of blood but has no known contribution to hemostasis, we sought to determine the thrombogenic role of FXII in an acute ex vivo venous stent model utilizing a FXII-neutralizing monoclonal antibody, 5C12.

UR - http://www.scopus.com/inward/record.url?scp=85065386728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065386728&partnerID=8YFLogxK

M3 - Conference contribution

AN - SCOPUS:85065386728

T3 - Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium

BT - Society for Biomaterials Annual Meeting and Exposition 2019

PB - Society for Biomaterials

ER -